A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...

Takers of GLP-1 are reportedly going on a "holiday pause" to enjoy meal centric family celebrations. Here, an MD breaks down ...

There has been a lot of conversation lately about if new weight loss drugs like Wegovy and Mounjaro should be covered by ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD).

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

Strata Decision Technology data finds the number of bariatric surgeries in the Chicago area may have fallen by more than half ...

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.

If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs ...

A study of 14,000 WeightWatchers participants is the latest to suggest that Ozempic and similar obesity drugs could be ...